A citation-based method for searching scientific literature

Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
Times Cited: 1160







List of co-cited articles
648 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
19

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
615
18

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
17

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
17

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
633
14

Idiopathic pulmonary fibrosis.
Fernando J Martinez, Harold R Collard, Annie Pardo, Ganesh Raghu, Luca Richeldi, Moises Selman, Jeffrey J Swigris, Hiroyuki Taniguchi, Athol U Wells. Nat Rev Dis Primers 2017
412
13

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
13


Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
T Ashcroft, J M Simpson, V Timbrell. J Clin Pathol 1988
979
8

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
8

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
411
8

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
Peter M George, Athol U Wells, R Gisli Jenkins. Lancet Respir Med 2020
467
8

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever. Eur Respir J 2015
397
8

Pathogenesis of idiopathic pulmonary fibrosis.
Paul J Wolters, Harold R Collard, Kirk D Jones. Annu Rev Pathol 2014
425
7


Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
Tasha E Fingerlin, Elissa Murphy, Weiming Zhang, Anna L Peljto, Kevin K Brown, Mark P Steele, James E Loyd, Gregory P Cosgrove, David Lynch, Steve Groshong,[...]. Nat Genet 2013
459
7


An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
6

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
950
6



Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
6

Inflammation and immunity in IPF pathogenesis and treatment.
P Heukels, C C Moor, J H von der Thüsen, M S Wijsenbeek, M Kool. Respir Med 2019
115
6

Developmental pathways in the pathogenesis of lung fibrosis.
Diptiman Chanda, Eva Otoupalova, Samuel R Smith, Thomas Volckaert, Stijn P De Langhe, Victor J Thannickal. Mol Aspects Med 2019
127
6

The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.
Andrew M Tager, Peter LaCamera, Barry S Shea, Gabriele S Campanella, Moisés Selman, Zhenwen Zhao, Vasiliy Polosukhin, John Wain, Banu A Karimi-Shah, Nancy D Kim,[...]. Nat Med 2008
526
6

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis.
Taylor S Adams, Jonas C Schupp, Sergio Poli, Ehab A Ayaub, Nir Neumark, Farida Ahangari, Sarah G Chu, Benjamin A Raby, Giuseppe DeIuliis, Michael Januszyk,[...]. Sci Adv 2020
227
6


Cellular senescence mediates fibrotic pulmonary disease.
Marissa J Schafer, Thomas A White, Koji Iijima, Andrew J Haak, Giovanni Ligresti, Elizabeth J Atkinson, Ann L Oberg, Jodie Birch, Hanna Salmonowicz, Yi Zhu,[...]. Nat Commun 2017
621
6

Pulmonary fibrosis: patterns and perpetrators.
Paul W Noble, Christina E Barkauskas, Dianhua Jiang. J Clin Invest 2012
299
6

Matrix abnormalities in pulmonary fibrosis.
Chandak Upagupta, Chiko Shimbori, Rahmah Alsilmi, Martin Kolb. Eur Respir Rev 2018
86
5

Molecular and cellular mechanisms of pulmonary fibrosis.
Nevins W Todd, Irina G Luzina, Sergei P Atamas. Fibrogenesis Tissue Repair 2012
241
5

Idiopathic pulmonary fibrosis: pathogenesis and management.
Giacomo Sgalla, Bruno Iovene, Mariarosaria Calvello, Margherita Ori, Francesco Varone, Luca Richeldi. Respir Res 2018
180
5

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Toby M Maher, Ellen M van der Aar, Olivier Van de Steen, Lisa Allamassey, Julie Desrivot, Sonia Dupont, Liesbeth Fagard, Paul Ford, Ann Fieuw, Wim Wuyts. Lancet Respir Med 2018
117
5

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
Toby M Maher, Michael Kreuter, David J Lederer, Kevin K Brown, Wim Wuyts, Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, Walid Abi-Saab,[...]. BMJ Open Respir Res 2019
47
10

The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
Antje Moeller, Kjetil Ask, David Warburton, Jack Gauldie, Martin Kolb. Int J Biochem Cell Biol 2008
613
5


Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis.
Paul A Reyfman, James M Walter, Nikita Joshi, Kishore R Anekalla, Alexandra C McQuattie-Pimentel, Stephen Chiu, Ramiro Fernandez, Mahzad Akbarpour, Ching-I Chen, Ziyou Ren,[...]. Am J Respir Crit Care Med 2019
456
5

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
952
5

Mechanisms of pulmonary fibrosis.
Victor J Thannickal, Galen B Toews, Eric S White, Joseph P Lynch, Fernando J Martinez. Annu Rev Med 2004
469
5

Immune dysregulation as a driver of idiopathic pulmonary fibrosis.
Kevin Shenderov, Samuel L Collins, Jonathan D Powell, Maureen R Horton. J Clin Invest 2021
28
17

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
621
5

Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.
Ana L Mora, Mauricio Rojas, Annie Pardo, Moises Selman. Nat Rev Drug Discov 2017
154
5

IPF lung fibroblasts have a senescent phenotype.
Diana Álvarez, Nayra Cárdenes, Jacobo Sellarés, Marta Bueno, Catherine Corey, Vidya Sagar Hanumanthu, Yating Peng, Hannah D'Cunha, John Sembrat, Mehdi Nouraie,[...]. Am J Physiol Lung Cell Mol Physiol 2017
142
5

Epithelial⁻Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis.
Francesco Salton, Maria Concetta Volpe, Marco Confalonieri. Medicina (Kaunas) 2019
69
7

Fibrotic disease and the T(H)1/T(H)2 paradigm.
Thomas A Wynn. Nat Rev Immunol 2004
5

Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis.
Thị Hằng Giang Phan, Panagiotis Paliogiannis, Gheyath K Nasrallah, Roberta Giordo, Ali Hussein Eid, Alessandro Giuseppe Fois, Angelo Zinellu, Arduino Aleksander Mangoni, Gianfranco Pintus. Cell Mol Life Sci 2021
57
8

Type 2 alveolar cells are stem cells in adult lung.
Christina E Barkauskas, Michael J Cronce, Craig R Rackley, Emily J Bowie, Douglas R Keene, Barry R Stripp, Scott H Randell, Paul W Noble, Brigid L M Hogan. J Clin Invest 2013
848
5

Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.
Brent W Kinder, Kevin K Brown, Marvin I Schwarz, Joachim H Ix, Alma Kervitsky, Talmadge E King. Chest 2008
163
4

Molecular mechanisms of epithelial-mesenchymal transition.
Samy Lamouille, Jian Xu, Rik Derynck. Nat Rev Mol Cell Biol 2014
4

TGF-β Signaling in Lung Health and Disease.
Akira Saito, Masafumi Horie, Takahide Nagase. Int J Mol Sci 2018
147
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.